Login to Your Account

Immatics’ Series D Adds $46M for Phase III Renal Cancer Trial

By Nuala Moran
Staff Writer

Wednesday, October 16, 2013

LONDON – Immatics Biotechnologies GmbH has closed a 34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription